Last updated on October 2017

Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease


Brief description of study

A randomized, controlled pilot trial to evaluate the efficacy and safety of subcutaneous Abatacept in treating interstitial lung disease associated with the anti-synthetase syndrome.

Detailed Study Description

This is a proof of concept study to evaluate the efficacy, safety and tolerability of ABT in Syn-ILD in a multi-center randomized, placebo-controlled 6-month (24-week) pilot study.

Clinical Study Identifier: NCT03215927

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Swamy Venuturupalli, MD

Cedars-Sinai Medical Center
Beverly Hills, CA United States
  Connect »

Aryeh Fischer, MD

University of Colorado Anschutz Medical Campus
Denver, CO United States
  Connect »

Cheilonda Johnson, MD, MHS

John Hopkins Medical Center
Baltimore, MD United States
  Connect »

Paul F. Dellaripa, MD

Brigham & Women's Hospital
Boston, MA United States
  Connect »

Rohit Aggarwal, MD

University of Pittsburgh
Pittsburgh, PA United States
  Connect »